Capsaicin ( DrugBank: Capsaicin )

5 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
2	筋萎縮性側索硬化症	3
6	パーキンソン病	3
19	ライソゾーム病	1
86	肺動脈性肺高血圧症	2
226	間質性膀胱炎（ハンナ型）	1

2. 筋萎縮性側索硬化症

臨床試験数 : 624 / 薬物数 : 611 - (DrugBank : 160) / 標的遺伝子数 : 172 - 標的パスウェイ数 : 225

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02962050 (ClinicalTrials.gov)	May 31, 2017	4/11/2016	Delineating Swallowing Impairment and Decline in ALS	Delineating Physiologic Mechanisms of Swallowing Impairment and Decline in ALS	Amyotrophic Lateral Sclerosis	Procedure: Videofluoroscopic Swallowing Study (VFSS);Device: Voluntary Peak Cough Flow Testing;Device: Iowa Oral Performance Instrument;Drug: Capsaicin Challenge;Device: Pulmonary Function Testing;Other: Eating Assessment Tool 10;Other: The Center for Neurologic Study Bulbar Function Scale	University of Florida	National Institute of Neurological Disorders and Stroke (NINDS)	Recruiting	18 Years	90 Years	All	110		United States
2	NCT02710162 (ClinicalTrials.gov)	April 2016	29/2/2016	Accurate Screening Tools for Dysphagia in Amyotrophic Lateral Sclerosis (ALS)	Determination of Accurate Screening Tools for Dysphagia in Amyotrophic Lateral Sclerosis (ALS)	Amyotrophic Lateral Sclerosis	Device: Micro Mouth Pressure Meter;Device: Iowa Oral Performance Instrument;Device: Electrical Impedance Myography;Drug: Capsaicin;Procedure: Videofluoroscopic Swallowing Study;Procedure: Pulmonary Function Testing;Other: Swallowing Related Quality of Life Questionnaire;Other: Functional Oral Intake Scale;Other: Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised;Other: Eating Assessment Tool-10;Other: Communicative Effectiveness Survey;Other: The Center for Neurologic Studies Bulbar Function Scale	University of Florida	NULL	Completed	21 Years	85 Years	All	21	Early Phase 1	United States
3	NCT02710110 (ClinicalTrials.gov)	April 2016	26/2/2016	Respiratory Strength Training in Persons With Amyotrophic Lateral Sclerosis (ALS)	The Impact of Respiratory Strength Training in Individuals With Amyotrophic Lateral Sclerosis (ALS)	Amyotrophic Lateral Sclerosis	Device: PowerLung trainer;Device: Micro Mouth Pressure Meter;Procedure: Pulmonary Function Testing;Procedure: Videofluoroscopic swallowing study;Other: Swallowing Quality of Life Questionnaire;Device: Iowa Oral Pressure Instrument;Drug: Capsaicin	University of Florida	ALS Association	Completed	21 Years	85 Years	All	50	Early Phase 1	United States

6. パーキンソン病

臨床試験数 : 2,298 / 薬物数 : 2,202 - (DrugBank : 350) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03321019 (ClinicalTrials.gov)	December 12, 2017	20/10/2017	Airway Protective Mechanisms in PD (R01)	Mechanisms of Airway Protection Dysfunction in Parkinson's Disease	Parkinson Disease	Drug: Capsaicin;Device: Resistive respiratory loads;Other: Event-related evoked potential using electroencephalography (EEG).;Procedure: Fluoroscopic swallow evaluation	University of Florida	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Recruiting	45 Years	85 Years	All	260		United States
2	NCT02390089 (ClinicalTrials.gov)	April 2015	19/2/2015	Cough According to Stimulus Type in PD	Airway Protection Deficits According to Stimulus Type in Parkinson's Disease	Parkinson's Disease	Drug: Capsaicin vapor;Other: fog;Radiation: Videofluoroscopic swallow evaluation;Device: Nebulizer	University of Florida	National Institute on Deafness and Other Communication Disorders (NIDCD)	Completed	50 Years	80 Years	All	158	Phase 1	United States
3	NCT02183519 (ClinicalTrials.gov)	October 2014	2/7/2014	Respiratory Kinematics of Cough in Healthy Older Adults and Parkinson's Disease	Respiratory Kinematics of Reflex and Voluntary Cough in Healthy Older Adults and Parkinson's Disease	Cough;Parkinson's Disease	Drug: Capsaicin;Other: Voluntary cough test	University of Florida	NULL	Completed	55 Years	85 Years	All	44	Phase 1/Phase 2	United States

19. ライソゾーム病

臨床試験数 : 854 / 薬物数 : 716 - (DrugBank : 105) / 標的遺伝子数 : 70 - 標的パスウェイ数 : 191

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02533076 (ClinicalTrials.gov)	November 2014	14/7/2015	The Functional Consequences of the CTNS-deletion for the TRPV1-receptor in Cystinosis Patients	The Functional Consequences of the CTNS-deletion for the TRPV1-receptor in Cystinosis Patients	Cystinosis	Other: Challenge agent: capsaicin;Other: Challenge agent: placebo;Device: Mechanical stimulation with Von Frey filaments;Device: Temperature sensitivity measurement with Advanced Thermal Stimulation	Universitaire Ziekenhuizen Leuven	NULL	Completed	8 Years	N/A	Both	50	Phase 0	Belgium

86. 肺動脈性肺高血圧症

臨床試験数 : 1,181 / 薬物数 : 701 - (DrugBank : 126) / 標的遺伝子数 : 105 - 標的パスウェイ数 : 192

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2011-001312-59-GB (EUCTR)	24/06/2011	15/04/2011	A double-blinded, randomized, crossover clinical study to assess the efficacy of Qutenza (capsaicin 8% patches) for the reduction of site pain caused by continuous subcutaneous infusion of Remodulin (treprostinil sodium), in Pulmonary Arterial Hypertension Patients - Efficacy of capsaicin 8% patches in Pulmonary Arterial Hypertension	A double-blinded, randomized, crossover clinical study to assess the efficacy of Qutenza (capsaicin 8% patches) for the reduction of site pain caused by continuous subcutaneous infusion of Remodulin (treprostinil sodium), in Pulmonary Arterial Hypertension Patients - Efficacy of capsaicin 8% patches in Pulmonary Arterial Hypertension	Pulmonary arterial hypertension (PAH) is a rare life-threatening disease characterised by high blood pressure in the arteries to the lungs, rapidly evolving in a clinical syndrome of dyspnoea and fatigue and eventually leading to right ventricular failure and death. MedDRA version: 13.1;Level: PT;Classification code 10037400;Term: Pulmonary hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders	Trade Name: Qutenza Product Name: Qutenza INN or Proposed INN: Capsaicin	Imperial College London	NULL	Not Recruiting			Female: yes Male: yes	0		United Kingdom
2	NCT01260454 (ClinicalTrials.gov)	November 2010	9/12/2010	The Qutenza Patch as Treatment for Disabling Treprostinil (Remodulin) Infusion Site Pain	The Qutenza® Patch for Disabling Treprostinil Infusion Site Pain	Pulmonary Hypertension;Pulmonary Arterial Hypertension	Drug: Qutenza (8% capsaicin)	University of Rochester	United Therapeutics	Completed	15 Years	80 Years	All	6	Phase 2	United States

226. 間質性膀胱炎（ハンナ型）

臨床試験数 : 143 / 薬物数 : 171 - (DrugBank : 56) / 標的遺伝子数 : 64 - 標的パスウェイ数 : 145

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00004316 (ClinicalTrials.gov)	June 1995	18/10/1999	Phase I/II Randomized, Placebo-Controlled Study of Capsaicin for Interstitial Cystitis and Vulvar Vestibulitis		Interstitial Cystitis;Vulvar Diseases	Drug: capsaicin	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	University of Pittsburgh	Completed	18 Years	N/A	Female	139	Phase 1/Phase 2	NULL

先頭へ